Table 1.

C35 expression in FFPE breast tissue sections was determined by immunohistochemistry

	n	HER-2/neu⁺ (%)	C35⁺ (%)	Mean C35 reactivity	P (one-sample paired t)
Intraductal carcinoma
Qualtek study	57	21	53
AccuMax Array	30	20	40
Asterand Array	71	20	38
Total IDC	158	20*	44	1.46^†	<0.0001

Low grade (1)	22	0	32	0.73
High grade (2 and 3)	35	34	66	2.03^†	<0.0001

Stage I	28	11	18	0.93
Stage II	38	24	47	1.63^†	<0.0001
Stage III	26	19	38	1.46^†	0.0035
Stage IV	4	25	50	1.75

Lobular carcinoma
Qualtek Study	14	0	50
AccuMax Array	4	0	25
Asterand Array	22	5	32
Total ILC	40	5^‡	38	1.16^†	0.0083

Papillary carcinoma: AccuMax	8	13*	50	1.13
Medullary carcinoma: Asterand	6	0	0
Mucinous carcinoma: Asterand	2	0	50

Normal breast tissue
Adjacent normal	40		13
Normal breast	17		35
Total normal breast	57		19	0.61

↵* All HER-2/neu⁺ samples are also C35⁺.
↵† Significant difference compared with expression in normal breast by paired t test (P < 0.05).
↵‡ The two HER-2/neu⁺ samples are C35⁻.